Diagnostic company merges with investment house:
This article was originally published in Clinica
Executive Summary
Pathobiotek Diagnostics is to merge with Investra Enterprises to allow it to continue its acquisition programme and to maintain its position on the Nasdaq over-the-counter listings. The Houston, Texas-based Pathobiotek is developing products for the diagnosis and treatment monitoring in multiple sclerosis and other immune diseases.